1932

Abstract

Randomized trials have studied bisphosphonates in the adjuvant setting of early breast cancer to investigate their ability to prevent treatment-induced bone loss. Trial results have also suggested their potential to prevent disease recurrence and metastases. These trials are summarized in this review. A recent patient-level meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) finds convincing evidence that adjuvant antiresorptive treatments provide persistent benefits to breast cancer patients in low-estrogen situations and should be considered an important part of the treatment algorithm.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-053014-103600
2016-01-14
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-053014-103600.html?itemId=/content/journals/10.1146/annurev-med-053014-103600&mimeType=html&fmt=ahah

Literature Cited

  1. 1. American Cancer Society 2011. Global Cancer Facts and Figures. Atlanta, GA: Am. Cancer Soc, 2nd ed..
  2. Gnant M, Steger GC. 2.  2009. Fighting overtreatment in adjuvant breast cancer therapy. Lancet 374:2029–30 [Google Scholar]
  3. Body JJ. 3.  2011. Increased fracture rate in women with breast cancer: a review of the hidden risk. BMC Cancer 11:384 [Google Scholar]
  4. Gnant M. 4.  2014. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat. Rev. 40:476–84 [Google Scholar]
  5. Powles TJ, Paterson A, McCloskey E. 5.  et al. 2006. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res. Treat. 8:R13 [Google Scholar]
  6. 6. Early Breast Cancer Trialists' Collaborative Group 2015. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 3861353–61
  7. Hadji P, Coleman R, Gnant M. 7.  et al. 2012. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann. Oncol. 23:2782–90 [Google Scholar]
  8. Coleman R, Body JJ, Aapro M. 8.  et al. 2014. Bone health in cancer patient: ESMO Clinical Practice Guidelines. Ann. Oncol. 25:Suppl. 3124–37 [Google Scholar]
  9. Becker T, Lipscombe L, Narod S. 9.  et al. 2012. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J. Am. Geriatr. Soc. 60:1761–67 [Google Scholar]
  10. Gnant M, Mlineritsch B, Stoeger H. 10.  et al. 2008. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9:840–49 [Google Scholar]
  11. Coleman R, de Boer R, Eidtmann H. 11.  et al. 2013. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann. Oncol. 24:398–405 [Google Scholar]
  12. Paterson AH, Anderson SJ, Lembersky BC. 12.  et al. 2012. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13:734–42 [Google Scholar]
  13. Hadji P, Aapro MS, Body JJ. 13.  et al. 2011. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann. Oncol. 22:2546–55 [Google Scholar]
  14. Diel IJ, Jaschke A, Solomayer EF. 14.  et al. 2008. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-up. Ann. Oncol. 19:2007–11 [Google Scholar]
  15. Gnant M, Mlineritsch B, Schippinger W. 15.  et al. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360:679–91 [Google Scholar]
  16. Coleman RE. 16.  et al. 2011. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365:1396–405 [Google Scholar]
  17. Gnant M, Clezardin P. 17.  2012. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat. Rev. 38:407–15 [Google Scholar]
  18. Coleman R, Gnant M, Morgan G, Clezardin P. 18.  2012. Effects of bone-targeted agents on cancer progression and mortality. J. Natl. Cancer Inst. 104:1059–67 [Google Scholar]
  19. Von Minckwitz G, Möbus V, Schneeweiss A. 19.  et al. 2013. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J. Clin. Oncol. 31:283531–39 [Google Scholar]
  20. Paget S. 20.  1889. The distribution of secondary growths in cancer of the breast. Lancet 133:571–73 [Google Scholar]
  21. Mundy GR. 21.  1997. Mechanisms of bone metastasis. Cancer 80:1546–56 [Google Scholar]
  22. Brown HK, Ottewell PD, Evans CA. 22.  et al. 2012. Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin. Exp. Metastasis 29:927–38 [Google Scholar]
  23. Kollet O, Dar A, Shivtiel S. 23.  et al. 2006. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12:657–64 [Google Scholar]
  24. Kaplan RN, Rafii S, Lyden D. 24.  2006. Preparing the “soil”: the premetastatic niche. Cancer Res. 66:11089–93 [Google Scholar]
  25. Holen I, Coleman RE. 25.  2010. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 12:6214 [Google Scholar]
  26. Yin JJ, Selander K, Chirgwin JM. 26.  et al. 1999. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103:197–206 [Google Scholar]
  27. Schramek D, Leibbrandt A, Sigl V. 27.  et al. 2010. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98–102 [Google Scholar]
  28. Meads MB, Hazelhurst LA, Dalton WS. 28.  2008. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14:2519–26 [Google Scholar]
  29. Coleman R. 29.  1997. Skeletal complications of malignancy. Cancer 80:1588–94 [Google Scholar]
  30. Le Gall C, Bellahcène A, Bonnelye E. 30.  et al. 2007. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67:209894–902 [Google Scholar]
  31. Koeneman KS, Yeung F, Chung LW. 31.  1999. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246–61 [Google Scholar]
  32. Ottewell PD, Wang N, Brown HK. 32.  et al. 2014. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20:2922–32 [Google Scholar]
  33. Rennert G, Pinchev M, Rennert HS. 33.  2010. Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol. 28:3577–81 [Google Scholar]
  34. Azim HA, Kamal NS, Malak RA. 34.  2013. Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!. J. Thorac. Dis. 5:Suppl. 1S27–S35 [Google Scholar]
/content/journals/10.1146/annurev-med-053014-103600
Loading
/content/journals/10.1146/annurev-med-053014-103600
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error